Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher.
The iShares Biotechnology ETF (IBB) added 0.1%.
In corporate news, Vor Biopharma (VOR) shares surged 80%, a day after the company signed a license deal with RemeGen for global rights, excluding Greater China, to develop and commercialize telitacicept for autoimmune diseases.
3D Systems (DDD) shares popped 7% after the firm said collaboration with Tissium has resulted in US Food and Drug Administration approval for 3D-printed polymeric solution for repair of peripheral nerve damage.
Walgreens Boots Alliance (WBA) reported fiscal Q3 results above market estimates, even though the drugstore chain was weighed down by weakness in US retail sales. The shares rose 0.5%.
Novo Nordisk (NVO) entered into a collaboration with WeightWatchers to expand patient access to its weight-loss drug Wegovy. Novo shares added 0.5%.
ReShape Lifesciences (RSLS) shares fell 3%. The firm plans to cut jobs to save $750,000, or 23% of annual payroll expenses.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。